Navigation Links
Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
Date:9/29/2008

SEATTLE, Sept. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) will host an investor and media day in Milan, Italy on October 3, 2008. The investor day will provide an update from executive management on key strategic initiatives and regulatory milestones for the Company. Additionally, Alessandro Gianni, M.D., Director of the School of Specialization in Medical Oncology at the University of Milan, who has authored over 300 publications will be a guest speaker at the event and will provide a key perspective on the benefits of Zevalin(R) (([90Y]-ibritumomab tiuxetan) in the treatment of follicular non-Hodgkin's lymphoma. The meeting is an invitation-only event. A webcast and live teleconference of the event is available to all investors.

Webcast and Teleconference Details

Date: Friday, October 3, 2008

Time: 7:00 a.m. Eastern/1:00 p.m. Central European/4:00 a.m. Pacific Time

Conference Call Numbers

1-866-239-6425 (US Participants)

+39 02 80 20 911 (Italy)

+44 208 7929 750 (Europe)

Call-back numbers for post-listening

1-866-848-9310 (US Participants)

+39 02 80 61 3780 (Italy)

+44 207 1086 235 (Europe)

Passcode:

English: 741

Italian: 740

Live audio webcast at http://www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.272.4345

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
3. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
4. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
5. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
6. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
7. FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion
8. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
9. Synvista Therapeutics Posts Letter to Stockholders on Web Site
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):